Transplantation of human umbilical cord blood mesenchymal stem cells in the repair of hematopoietic injury in bone marrow

doi:10.3969/j.issn.2095-4344.2103

Abstract

Abstract:

BACKGROUND: A large number of studies mainly concern the proliferation effect of mesenchymal stem cells on hematopoietic stem cells in vitro and that bone marrow mesenchymal stem cell transplantation can reduce the death of hematopoietic cells caused by irradiation, increase the survival of bone marrow cells and repair hematopoiesis, while few of them investigate the repair of human umbilical cord blood mesenchymal stem cells transplantation on bone marrow hematopoiesis injury.

OBJECTIVE: To explore the repair of hematopoietic microenvironment of bone marrow by human umbilical cord blood mesenchymal stem cells.

METHODS: Male BALB/c mice were randomly divided into three groups. The mice in experimental group and control group were irradiated with total dose of 6-Gy X-ray to establish a mouse model of bone marrow hematopoietic injury. The normal group contained untreated normal mice. In the experimental group, CM-DiL labeled human umbilical cord blood mesenchymal stem cells were injected into the tail vein of each mouse at 5×10⁶ (0.2 mL). The control group and the normal group received normal saline 0.2 mL through the tail vein. The peripheral blood hematology and bone marrow hematopoietic microenvironment repair were observed at 1, 5, 7, 14 and 21 days after cell transplantation.

RESULTS AND CONCLUSION: Peripheral blood condition: At 1, 5 and 7 days after transplantation, the leucocyte, platelet, erythrocyte count and hemoglobin concentration in the experimental group and control group decreased progressively compared with the normal group. The most obvious decrease occurred on day 7. The trilineage recovered on day 14 after transplantation, basically returned to normal on day 21 after transplantation. Compared with the experimental group, the decrease of the trilineage in the control group was more obvious. The recovery was obvious faster in the experimental group than in the control group on day 14 after transplantation. Bone marrow smears: Bone marrow smears showed that the hematopoietic function was inhibited in the experimental group and the control group at 1, 5, 7, and 14 days after transplantation, especially on day 7. Bone marrow proliferation recovered on day 14 after transplantation. It was better in the experimental group than in the control group. On day 21 after transplantation, the hematopoietic function of bone marrow of mice in the experimental group and the control group recovered, and there was no difference between the experimental group and the control group compared with the normal group. Bone marrow pathological section: Bone marrow pathological sections showed that at 1, 5, 7, and 14 days after transplantation, the hematopoietic function of bone marrow in the experimental group and the control group was inhibited. On day 14 after transplantation, the bone marrow hematopoietic function of the experimental group and the control group began to recover, but the bone marrow proliferation of the experimental group was better than that of the control group. On day 21 after transplantation, there was no difference in the bone marrow proliferation between the experimental and the control groups and the normal group. The results suggested that human umbilical cord blood mesenchymal stem cells can promote the recovery of hematopoietic function of bone marrow.

Key words:

human umbilical cord blood mesenchymal stem cells, bone marrow hematopoiesis, hematopoietic function, bone marrow hyperplasia

CLC Number:

Gao Kunli, Xing Hongyun, Bian Tierong, Han Liying.

Transplantation of human umbilical cord blood mesenchymal stem cells in the repair of hematopoietic injury in bone marrow [J]. Chinese Journal of Tissue Engineering Research, 2020, 24(25): 3966-3972.

Figures/Tables 12

References

[1] SPRADLING A, DRUMMOND-BARBOSA D, KAI T. Stem cells find their niche. Nature. 2001;414(6859):98-104.

[2] LUCAS D. The Bone Marrow Microenvironment for Hematopoietic Stem Cells. Adv Exp Med Biol. 2017;1041:5-18.

[3] 张之南.协和血液病学[M].北京:中国协和医科大学出版社,2004:25.

[4] KUÇI S, KUÇI Z, KREYENBERG H, et al. CD271 antigen defines a subset of multipotent stromal cells with immunosuppressive and lymphohematopoietic engraftment-promoting properties. Haematologica. 2010;95(4):651-659.

[5] DAR A, GOICHBERG P, SHINDER V, et al. Chemokine receptor CXCR4-dependent internalization and resecretion of functional chemokine SDF-1 by bone marrow endothelial and stromal cells. Nat Immunol. 2005;6(10):1038-1046.

[6] WEISS ML, ANDERSON C, MEDICETTY S, et al. Immune properties of human umbilical cord Wharton's jelly-derived cells. Stem Cells. 2008;26(11):2865-2874.

[7] 张积华,孙康,王妍,等.脐血间充质干细胞生物学特性及其成骨成脂分化潜能[J].中国组织工程研究与临床康复,2010,14(27): 4984-4987.

[8] WEISS ML, MEDICETTY S, BLEDSOE AR, et al. Human umbilical cord matrix stem cells: preliminary characterization and effect of transplantation in a rodent model of Parkinson's disease. Stem Cells. 2006;24(3):781-792.

[9] WEIR C, MOREL-KOPP MC, GILL A, et al. Mesenchymal stem cells: isolation, characterisation and in vivo fluorescent dye tracking. Heart Lung Circ. 2008;17(5):395-403.

[10] SCHORMANN W, HAMMERSEN FJ, BRULPORT M, et al. Tracking of human cells in mice. Histochem Cell Biol. 2008; 130(2):329-338.

[11] 张曦,司英健,陈幸华,等.Co60 γ辐照对裸鼠血像及造血微环境功能影响的动态观察[J].检验医学与临床,2008,5(3):129-132.

[12] 汪姝玥,林凡莉,钱怡,等.不同共培养模式下间充质干细胞对造血干细胞增殖的作用[J].中国组织工程研究,2018,22(13):2068-2074.

[13] 张曦,陈幸华,刘林.外周血干细胞移植患者骨髓基质细胞粘附功能的变化[J].医学研究生学报,2003,16(8):590-593.

[14] 胡锴勋,孙琪云,艾辉胜,等.间充质干细胞治疗急性骨髓型放射病的实验研究[J].中华放射医学与防护杂志,2005,25(3):221-224.

[15] WALENDA T, BOKERMANN G, VENTURA FERREIRA MS, et al. Synergistic effects of growth factors and mesenchymal stromal cells for expansion of hematopoietic stem and progenitor cells. Exp Hematol. 2011;39(6):617-628.

[16] ZHANG C, CHEN XH, ZHANG X, et al. Human umbilical cord blood-derived stromal cells: a new resource in hematopoietic reconstitution in mouse haploidentical transplantation. Transplant Proc. 2010;42(9):3739-3744.

[17] MATSUOKA Y, NAKATSUKA R, SUMIDE K, et al. Prospectively Isolated Human Bone Marrow Cell-Derived MSCs Support Primitive Human CD34-Negative Hematopoietic Stem Cells. Stem Cells. 2015;33(5):1554-1565.

[18] PONTIKOGLOU C, DESCHASEAUX F, SENSEBÉ L, et al. Bone marrow mesenchymal stem cells: biological properties and their role in hematopoiesis and hematopoietic stem cell transplantation. Stem Cell Rev Rep. 2011;7(3):569-589.

[19] OVERHOLT KM, OTSURU S, OLSON TS, et al. Identification of a murine CD45-F4/80lo HSC-derived marrow endosteal cell associated with donor stem cell engraftment. Blood Adv. 2017; 1(27):2667-2678.

[20] CAO B, ZHANG Z, GRASSINGER J, et al. Therapeutic targeting and rapid mobilization of endosteal HSC using a small molecule integrin antagonist. Nat Commun. 2016;7:11007.

[21] 尹利明,赵燕娜,杜文喜,等.人参总皂苷增强成骨分化的间充质干细胞促造血作用研究[J].中国药理学通报,2015,31(1):45-49.

[22] BARACHINI S, TROMBI L, DANTI S, et al. Morpho-functional characterization of human mesenchymal stem cells from umbilical cord blood for potential uses in regenerative medicine. Stem Cells Dev. 2009;18(2):293-305.

[23] MARKOV V, KUSUMI K, TADESSE MG, et al. Identification of cord blood-derived mesenchymal stem/stromal cell populations with distinct growth kinetics, differentiation potentials, and gene expression profiles. Stem Cells Dev. 2007;16(1):53-73.

[24] WANG TT, TIO M, LEE W, et al. Neural differentiation of mesenchymal-like stem cells from cord blood is mediated by PKA. Biochem Biophys Res Commun. 2007;357(4):1021-1027.

[25] PITTENGER MF, MACKAY AM, BECK SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999; 284(5411):143-147.